Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

CRH Medical Corp (CRHM)

CRH Medical Corp (CRHM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

CRH Medical Corp 619 - 999 CANADA PLACE WORLD TRADE CENTER VANCOUVER A1 V6C 3E1 CAN

investors.crhsystem.com P: 604-633-1440

Description:

CRH Medical Corporation is a North American company focused on providing gastroenterologists throughout the United States with innovative services and products for the treatment of gastrointestinal diseases. In 2014, CRH became a full-service gastroenterology anesthesia company that provides anesthesia services for patients undergoing endoscopic procedures in ambulatory surgical centers. At the end of 2018, CRH had completed 20 anesthesia acquisitions and served 46 ambulatory surgical centers in ten states, performing approximately 305,000 procedures annually. In addition, CRH owns the CRH O'Regan System, a single-use, disposable, hemorrhoid banding technology that is safe and highly effective in treating all grades of hemorrhoids. CRH distributes the O'Regan System, treatment protocols, operational and marketing expertise as a complete, turnkey package directly to gastroenterology practices, creating meaningful relationships with the gastroenterologists it serves.

Key Statistics

Overview:

Market Capitalization, $K 285,764
Shares Outstanding, K 71,620
Annual Sales, $ 106,170 K
Annual Net Income, $ -24,480 K
Last Quarter Sales, $ 36,780 K
Last Quarter Net Income, $ -19,150 K
60-Month Beta 2.58
% of Insider Shareholders 2.70%
% of Institutional Shareholders 42.11%
Float, K 69,686
% Float 97.30%

Growth:

1-Year Return 98.51%
3-Year Return 45.09%
5-Year Return 22.77%
5-Year Revenue Growth 130.55%
5-Year Earnings Growth -136.36%
5-Year Dividend Growth 0.00%

Per-Share Information:

Next Earnings Date 05/11/21
Earnings Per Share ttm -0.05
EPS Growth vs. Prev Qtr 400.00%
EPS Growth vs. Prev Year 50.00%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

CRHM Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward 399.00
Price/Earnings to Growth N/A
Return-on-Equity % -2.68%
Return-on-Assets % -1.57%
Profit Margin % -23.06%
Debt/Equity 0.67
Price/Sales 2.69
Price/Cash Flow 7.55
Price/Book 2.70
Book Value/Share 1.48
Interest Coverage -13.17
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar